MANNKIND CORP Long-Term Debt, Maturity, Remainder of Fiscal Year
MANNKIND CORP (MNKD) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2025-11-05
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2025-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2024-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2024-03-31 | $15.00M 10-Q · filed 2024-05-08 |
| 2023-09-30 | $5.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $6.67M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $11.67M 10-Q · filed 2023-05-09 |
| 2021-06-30 | $4.06M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $4.06M 10-Q · filed 2021-05-12 |
| 2020-09-30 | $4.25M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $4.25M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $5.26M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $5.26M 10-K · filed 2020-02-25 |
| 2017-09-30 | $10.00M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |